{
    "nct_id": "NCT05643638",
    "official_title": "A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids Vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease",
    "inclusion_criteria": "* Undergone allogeneic hematopoietic stem cell transplant (HSCT)\n* Clinically diagnosed with acute GvHD requiring systemic therapy with corticosteroids.\n* HR-aGvHD must meet one of the following clinical features within 72 hours prior to randomization: (a) high-risk as per Refined Minnesota Criteria; OR (b) One of the following: (i) isolated stage 2 involvement of the lower GI tract; (ii) Stage 1 lower GI tract disease with skin involvement\n* Evidence of myeloid engraftment post allogeneic HSCT\n* Life expectancy of at least one month\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received any systemic treatment for aGvHD other than corticosteroids +/- calcineurin inhibitors\n* Chronic GvHD or overlap syndrome with both acute and chronic features of GvHD\n* Relapsed primary malignancy since\n* received more than one allogeneic HSCT\n* Clinically significant respiratory, renal or cardiac disease\n* Cholestatic disorders or sinusoidal obstructive syndrome/veno-occlusive disease of the liver\n* Any active uncontrolled infection requiring treatment and likely to impact on the ability of the subject to participate in the trial.\n* Known infection with CMV, EBV, HHV-6, HBV, HCV, HIV or Tuberculosis. If the treatment for CMV, EBV, HHV-6, HBV, HCV has commenced the subject is eligible.\n* Known sensitivity to dimethylsulfoxide (DMSO) or any other component of CYP-001.\n* Received any investigational treatment agent within 30 days or within 5 half-lives of Screening, whichever is greater.",
    "miscellaneous_criteria": ""
}